Pioneer Trust Bank N A OR Boosts Stock Position in Eli Lilly and Company (NYSE:LLY)

Pioneer Trust Bank N A OR increased its stake in Eli Lilly and Company (NYSE:LLY) by 25.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 8,580 shares of the company’s stock after buying an additional 1,760 shares during the quarter. Pioneer Trust Bank N A OR’s holdings in Eli Lilly and Company were worth $5,001,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Baystate Wealth Management LLC lifted its position in Eli Lilly and Company by 26.1% in the 3rd quarter. Baystate Wealth Management LLC now owns 953 shares of the company’s stock valued at $512,000 after acquiring an additional 197 shares in the last quarter. North Point Portfolio Managers Corp OH lifted its holdings in shares of Eli Lilly and Company by 13.4% during the 3rd quarter. North Point Portfolio Managers Corp OH now owns 525 shares of the company’s stock valued at $282,000 after buying an additional 62 shares during the period. IFM Investors Pty Ltd lifted its holdings in shares of Eli Lilly and Company by 3.0% during the 3rd quarter. IFM Investors Pty Ltd now owns 164,045 shares of the company’s stock valued at $88,113,000 after buying an additional 4,790 shares during the period. High Note Wealth LLC lifted its holdings in shares of Eli Lilly and Company by 4.7% during the 3rd quarter. High Note Wealth LLC now owns 4,021 shares of the company’s stock valued at $2,160,000 after buying an additional 181 shares during the period. Finally, Waldron Private Wealth LLC lifted its holdings in shares of Eli Lilly and Company by 0.7% during the 3rd quarter. Waldron Private Wealth LLC now owns 13,838 shares of the company’s stock valued at $7,433,000 after buying an additional 95 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. Barclays increased their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Stock Performance

NYSE LLY traded down $3.45 during trading on Thursday, reaching $771.55. The company’s stock had a trading volume of 2,169,299 shares, compared to its average volume of 3,061,009. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The firm has a market cap of $733.28 billion, a price-to-earnings ratio of 114.27, a P/E/G ratio of 1.45 and a beta of 0.37. Eli Lilly and Company has a twelve month low of $419.80 and a twelve month high of $800.78. The business’s fifty day moving average price is $761.22 and its 200-day moving average price is $674.88.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the previous year, the business posted $1.62 earnings per share. The business’s revenue was up 26.0% compared to the same quarter last year. As a group, analysts anticipate that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.